Order: cefaclor 75 mg PO qhrs Available: cefaclor 125 mg/5 mL Child weighs: 10 kg Recommended child's drug dosage: 20-40 mg/kg/day Which of the following is true based on the provided information above?

This question evaluates effective interviewing techniques during the medication reconciliation process. It requires identifying open-ended questions that encourage comprehensive patient disclosure, allowing the nurse to gather essential information regarding all prescription, over-the-counter, and herbal products currently in use by the patient.

Choice A rationale

Asking what a patient takes for pain is a closed-ended question that yields limited information only about pain management. It fails to capture data about other medications, supplements, or health practices that the patient may be utilizing for other conditions.

Choice B rationale

Asking if a patient knows the side effects of their medications is a closed-ended, leading question that results in a simple yes or no response. It does not provide the nurse with detailed information about the patient's current medication use.

Choice C rationale

Asking why medications are taken at night assumes the patient takes them at night. This is a restrictive, leading question that fails to elicit a complete, patient-centered history regarding the full range of medications taken throughout the entire day.

Choice D rationale

Asking the patient to describe their medications is an open-ended question that encourages the patient to share detailed information in their own words. This approach fosters a comprehensive assessment, ensuring all medications, including OTC and herbal supplements, are reported.

This question tests the classification of insulins based on their pharmacokinetic profiles. It requires identifying the specific long-acting insulin analog that provides a relatively constant basal glycemic control without a pronounced peak for 24 hours, which is vital for safe diabetes management.

Choice A rationale

Insulin detemir is a long-acting insulin analog that has a variable duration of action, typically ranging from 12 to 24 hours depending on the administered dose. It does not provide a consistent, peakless 24-hour duration for all patients.

Choice B rationale

Insulin glargine is a long-acting insulin analog designed to provide a steady, peakless, basal insulin level for 24 hours. Its chemical structure allows for slow precipitation in subcutaneous tissue, ensuring continuous, consistent release throughout the full day for diabetic control.

Choice C rationale

Humulin R is a regular, short-acting insulin. It has a rapid onset and a relatively short duration of action, typically lasting 5 to 8 hours. It is used to cover meals or for glycemic correction, not as a long-acting basal insulin.

Choice D rationale

Lispro is a rapid-acting insulin analog with an onset within 15 minutes and a duration of only 3 to 4 hours. It is designed specifically to cover mealtime glucose spikes and is never used as a long-acting basal insulin therapy.